Metronidazole in the treatment of anaerobic infections

Area of Science:

• Medicine
• Infectious Diseases
• Pulmonology

Background:

• Anaerobic pleuropulmonary infections, including lung abscess, necrotizing pneumonia, and thoracic empyema, pose significant clinical challenges.
• Metronidazole is an antibiotic often considered for anaerobic infections, but its efficacy in complex pleuropulmonary cases requires further evaluation.

Purpose of the Study:

• To assess the effectiveness and safety of oral metronidazole in treating anaerobic pleuropulmonary infections.
• To determine the response rates of different anaerobic pleuropulmonary infections to metronidazole therapy.

Main Methods:

• A cohort of 13 adult patients with diagnosed anaerobic pleuropulmonary infections were treated with oral metronidazole (1.5-2 g daily).
• The study monitored treatment outcomes, including cure rates, treatment failures, and adverse events.
• Patient groups included those with lung abscess, necrotizing pneumonia, and thoracic empyema.

Main Results:

• Five out of 13 patients achieved a cure, with four of these having lung abscess.
• Five patients with lung abscess did not respond to metronidazole treatment.
• Treatment efficacy could not be evaluated in three patients due to various reasons, including refusal of medication, undrained empyema, and death.
• Reported side effects included leukopenia, neutropenia, dark urine, bitter taste, and epigastric distress.

Conclusions:

• Metronidazole demonstrated limited and non-uniform effectiveness in treating anaerobic pleuropulmonary infections.
• The antibiotic was particularly ineffective in treating lung abscesses in this patient cohort.
• Further research may be needed to identify optimal treatment strategies for these severe infections.